Novo Nordisk A/S ADR (NVO-N) Analyst Research & Price Targets - The Globe and Mail

Earnings Estimates

	Current Qtr03/2026	Next Qtr06/2026	Fiscal Yr12/2026	Fiscal Yr12/2027
Average Estimate	$0.87	$0.83	$3.37	$3.41
Number of Estimates	5	4	7	7
High Estimate	$0.94	$0.90	$3.72	$3.93
Low Estimate	$0.81	$0.77	$3.14	$3.03
Prior Year	$0.92	$0.97	$3.96	$3.37
Growth Rate Est. (year over year)	-5.43%	-14.43%	-14.90%	+1.19%

Earnings History - Surprises*

	Qtr Ending12/2025	Qtr Ending09/2025	Qtr Ending06/2025	Qtr Ending03/2025
Reported	$1.00	$1.02	$0.97	$0.92
Estimate	$0.90	$0.77	$0.93	$0.92
Difference	+0.10	+0.25	+0.04	unch
Surprise	+11.11%	+32.47%	+4.30%	unch

* Earnings are based on GAAP income from continuing operations.

Average Analyst Ratings

3.55

3 Mths Ago20

3.48

2 Mths Ago21

3.09

1 Mth Ago22

3.09

Current23

Ratings Values:

Strong Buy5

Moderate Buy4

Hold3

Moderate Sell2

Strong Sell1

Ratings Breakdown

	3 Mths Ago	2 Mths Ago	1 Mth Ago	Current
# of Analysts:	20	21	22	23
	7	7	2	2
Holds	11	12	19	20
	1 1	2	1	1

Key:

Strong Buy

Moderate Buy

Hold

Moderate Sell

Strong Sell

More from The Globe

Bullish on Pembina Pipeline Corp.

How investors should digest the stock market’s ‘sugar high’

Market Factors: Top picks, sector review for income-heavy utilities sector

The most oversold and overbought stocks on the TSX

The highest-yielding stocks on the TSX, plus risk data

Barlow’s Research Roundup: These stocks are biggest winners from oil price volatility

It’s not just Allbirds - another meme-stock season is on the horizon, Vanda Research says

Why did shares of GFL Environmental drop 10 per cent this week? Take our business and investing news quiz